4//SEC Filing
Ye Weiguo 4
Accession 0001140361-23-054520
CIK 0001124105other
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 7:49 PM ET
Size
5.8 KB
Accession
0001140361-23-054520
Insider Transaction Report
Form 4
Ye Weiguo
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-11-20+1,665,115→ 1,665,115 totalExercise: $0.75Exp: 2030-10-31→ Common Stock (1,665,115 underlying)
Footnotes (2)
- [F1]Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.
- [F2]These options are vested in full.
Documents
Issuer
GYRE THERAPEUTICS, INC.
CIK 0001124105
Entity typeother
Related Parties
1- filerCIK 0001985496
Filing Metadata
- Form type
- 4
- Filed
- Nov 21, 7:00 PM ET
- Accepted
- Nov 22, 7:49 PM ET
- Size
- 5.8 KB